HIV-1 treatment as prevention: The good, the bad, and the challenges

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 315-325

  Smith, Kumi ^a   Powers, Kimberly A ^a,b   Kashuba, Angela D M ^c   Cohen, Myron S ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina   (United States)

Author keywords

antiretroviral therapy; pre exposure prophylaxis; prevention

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; FEMALE GENITAL SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE GENITAL SYSTEM; MATHEMATICAL MODEL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH; RECTUM MUCOSA; REVIEW; SEXUAL TRANSMISSION; VAGINA DISCHARGE; VIRUS LOAD; VIRUS SHEDDING;

ANTI-HIV AGENTS; CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959371227     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834788e7     Document Type: Review

References (91)

1. Henry K, Chinnock BJ, Quinn RP, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988; 259:3023-3026.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174. This study is the first to report the results of a clinical trial demonstrating the effectiveness and safety of a 1%vaginal gel formulation of TDF for the prevention of HIV acquisition in women. Results show that the gel reduces HIV acquisition by an estimated 39% overall and by 54% in women with high gel adherence.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599. This study is the first to report the results of a clinical trial demonstrating the efficacy of oral preprophylactic effect (iPREX) in preventing HIV among MSM in Asia and Africa. More information is needed to evaluate possible subclinical effects such as low-level drug resistance as well as potential adjustments in HIV risk behavior among users.
4. Michael NL. Oral preexposure prophylaxis for HIV: another arrow in the quiver? N Engl J Med 2010; 363:2663-2665.
5. Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther 2010; 88:598-609.
6. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
7. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546-553.
8. Patterson K, Prince H, Kraft E, et al. Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single fixed dose of TDC/FTC: implications for preexposure HIV prophylaxis (PrEP). In: 18th International AIDS conference; 2010; Vienna, Austria.
9. Vourvahis M, Tappouni HL, Patterson KB, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 2008; 47:329-333. (Pubitemid 351619418)
10. Dumond JB, Reddy YS, Troiani L, et al. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr 2008; 48:156-162.
11. Bonora S, D'Avolio A, Simiele M, et al. Steady-state raltegravir penetration in seminal plasma of healthy volunteers. In: 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, California.
12. Brown K, Patterson K,Malone S, et al. Antiretrovirals for prevention: maraviroc exposure in the semen and rectal tissue of healthy male volunteers after single and multiple dosing. In: 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, California.
13. Brown KC, Patterson KB, Jennings SH, et al. Antiretrovirals for HIV prevention: darunavir + low dose ritonavir and etravirine exposure in the rectal tissue and seminal plasma of healthy male volunteers after single and multiple dosing. In: 18th Annual Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts
14. Fletcher P, Harman S, Azijn H, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53:487-495.
15. Brown L, Poole C, Patterson K, Cohen M. Variability in female genital tract shedding and plasma viral loads: a systematic review. In: 17th International AIDS Conference; 3-8 August 2008; Mexico City.
16. Chan DJ. Pathophysiology of HIV-1 in semen: current evidence for compartmentalization and penetration by antiretroviral drugs. Current HIV Res 2005; 3:207-222. (Pubitemid 41052422)
17. Le Tortorec A, Dejucq-Rainsford N. HIV infection in the male genital tract: consequences for sexual transmission and reproduction. Int J Androl 2010; 33:e98-e108.
18. Diem K, Nickle DC, Motoshige A, et al. Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). AIDS Res Hum Retroviruses 2008; 24:561-571. (Pubitemid 351571032)
19. Philpott S, Burger H, Tsoukas C, et al. Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol 2005; 79:353-363. (Pubitemid 39648389)
20. Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489-2497. This study determines patterns of genital tract HIV-1-RNA shedding over time among women with suppressed plasma viral load on ART.
21. Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050-2053.
22. Paredes R, Lalama CM, Ribaudo HJ, et al. Preexisting minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662-671. This study of the relationship between minority drug-resistant human HIV-1 and virologic failure in treated patients finds that in adherent patients, pre-existing minority Y181C mutants more than triple the risk of virologic failure of first-line efavirenz-based ART.
23. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
24. Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drugresistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201:1063-1071.
25. Toni TA, Asahchop EL, Moisi D, et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 2009; 53:1670-1672.
26. Anderson JA, Ping LH, Dibben O, et al. HIV-1 populations in semen arise through multiple mechanisms. PLoS Pathog 2010; 6:e1001053. doi: 10.1371/journal.ppat.1001053. This study compared HIV sequences in blood and semen using single gene amplification, a method that allows sensitive discrimination of these biological compartments. The results demonstrated that in some patient, blood and semen harbored similar viral variants, but that considerable divergence was possible. In addition, duplication of variants was observed in semen isolates, emphasizing ongoing viral replication in a closed compartment.
27. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303:2019-2022. (Pubitemid 38393277)
28. Harrison L, Castro H, Cane P, et al. The effect of transmitted HIV-1 drug resistance on pretherapy viral load. AIDS 2010; 24:1917-1922. In this study, the authors demonstrate detection of transmitted variants with drug resistance markers. They note that individuals infected with the M184 V/I variant had lower blood viral load, which they argue reflects a replication fitness cost associated with the mutation.
29. Murillo W, Paz-Bailey G, Morales S, et al. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol 2010; 49:239-244.
30. Balode D, Westman M, Kolupajeva T, et al. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. J Med Virol 2010; 82:2013-2018.
31. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200: 1503-1508.
32. Eyawo O, de Walque D, Ford N, et al. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:770-777. This systematic review finds that women are as likely as men to be the index partner in a discordant couple, highlighting the need to focus on both sexes in HIV prevention strategies.
33. Trask SA, Derdeyn CA, Fideli U, et al. Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol 2002; 76:397-405. (Pubitemid 33139024)
34. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1402-1409.
35. Gray R. The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. AIDS (in press). This research letter presented findings from a secondary analysis of the Rakai Cohort Study in which only a minority of new HIV infections was found to have occurred in the context of a stable HIV-discordant couple relationship.
36. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910. (Pubitemid 32881333)
37. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
38. Operskalski EA, Stram DO, Busch MP, et al. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol 1997; 146:655-661. (Pubitemid 27454553)
39. Pedraza MA, del Romero J, Roldan F, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999; 21:120-125. (Pubitemid 29250075)
40. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283. (Pubitemid 34208536)
41. Castilla J, del Romero G, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101. (Pubitemid 41233212)
42. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ 2010; 340:c2205. This article reports findings from a prospective study of 424 serodiscordant couples and finds an HIV seroconversion rate of 0-0.0005 per unprotected intercourse among the 144 couples in which the index partner was on ART. This finding suggests that heterosexual infectivity of HIV-1 in treated individuals may be very low.
43. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
44. Hernando V, del Romero G, Garcia S, et al. Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. Sex Transm Dis 2009; 36:621-628.
45. Melo MG, Santos BR, Lira RDC, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 2008; 35:912-915.
46. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994; 154:1971-1976. (Pubitemid 24276382)
47. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473-477.
48. Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV transmission risk and high risk sex while prescribed ART: results from discordant couples in Rwanda and Zambia. In: 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
49. Wang L, Ge Z, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010; 55:232-238. This article reports findings from a prospective study of 1927 serodiscordant couples. Authors report an HIV incidence rate of 1.71 per 100 person-years in which transmission events are equally distributed among couples whose index case was receiving or was not receiving ART.
50. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92. (Pubitemid 41818118)
51. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068. This study identified a positive association between decreases in total community viral load - measured as the sum of the most recent viral load of all reported HIV-positive individuals - and the era of expanded ART in San Francisco.
52. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-394. (Pubitemid 34184826)
53. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004; 18:81-88. (Pubitemid 38402321)
54. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885.
55. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67. (Pubitemid 351920290)
56. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536. (Pubitemid 44142776)
57. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539. Using mathematical models to analyze HIV surveillance data in British Columbia, the authors of this study claimed evidence of strong population-level associations among expanded ART coverage, decreased population viral load, and fewer annual HIV diagnoses between 1996 and 2009.
58. Shelton JD, Cohen M, Barnhart M, Hallett T. Is antiretroviral therapy modifying the HIV epidemic? Lancet 2010; 376:1824-1825; author reply 1825.
59. ·] on the association between ART coverage and community HIV viral load. Safer injection practices among IDUs is also highlighted as a likely confounder that could lead to overestimation of the association between expanded ART on lowered HIV incidence in British Columbia.
60. Dukers NHTM, Spaargaren J, Geskus RB, et al. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002; 16:F19-F24. (Pubitemid 34722061)
61. Stolte IG, Dukers NHTM, de Wit JBF, et al. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect 2001; 77:184-186. (Pubitemid 32595739)
62. Jansen IA, Geskus RB, Davidovich U, et al. Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS 2011; 25:493-501. This cohort study reports ongoing HIV-1 transmission among MSM in Amsterdam, particularly following increases in sexual risk behavior from 1996 onwards.
63. Jin F, Jansson J, Law M. Per-contact probability of HIV transmission in homosexual men in Sydney during the era of HAART. AIDS 2010; 24:907-913. A longitudinal cohort study of homosexual men in Australia found little difference in the per-contact probability of HIV transmission before and after widespread uptake of ART in HIV-infected men. The authors hypothesize that untreated STIs or unprotected sex during acute infection may partially explain the persistence of transmission even with high ART coverage.
64. Lima V, Williams B, Hogg R, et al. Why the MSM-driven HIV epidemic is not slowing down even in the presence of HAART. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, Massachusetts.
65. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
66. Le Vu S, Le Strat Y, Barin F, et al. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis 2010; 10:682-687. This analysis uses a stratified extrapolation model to estimate population incidence of HIV in France. Findings suggest that overall incidence in France is decreasing, but remains comparatively high among MSM.
67. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50 (Suppl 3):S85-S95.
68. Wilson DP, Garnett GP. Introduction to recent developments in HIV epidemic modeling. Curr Opin HIV AIDS 2011; 6:91-93.
69. Cambiano V, Phillips AN. Modelling the impact of treatment with individual antiretrovirals. Curr Opin HIV AIDS 2011; 6:124-130.
70. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
71. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314-320. (Pubitemid 352020440)
72. Law MG, Prestage G, Grulich A, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294. (Pubitemid 32592362)
73. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of preexposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 2010; 5:e13646. doi: 10.1371/journal. pone.0013646. This study models the potential impact of pre-exposure prophylaxis in averting new infections in South Africa and estimates a range in cost from $12 500 to $20 000 per infection averted, depending on the level of ART coverage and baseline incidence.
74. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400. This study applies a mathematical model to estimate the potential impact of an expanded HIV test and treat program in Washington, District of Columbia. The authors find that an intensive test and treat program - although expected to yield substantial benefits to individual patients - cannot be expected to stop the epidemic in Washington, District of Columbia, a finding that holds important implications for ongoing 'test and treat' strategies.
75. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 2010; 153:778-789. This article applies a dynamic mathematical model to perform a cost-effectiveness model of expanded ART, HIV screening, and behavioral interventions. The authors suggest that expanded screening and treatment offers a substantial public health impact, but are insufficient to reduce the US HIV epidemic without substantial reductions in risk behavior.
76. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: WHO Press; 2010. http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. [Accessed 19 February 2011]
77. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144. (Pubitemid 351590049)
78. Severe P, Pape J, Fitzgerald DW. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/ml (CIPRA HT 001). In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco, California.
79. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV - infected patients under HAART without any other sexually transmitted infection do not transmit HIV by sexual intercourse. Bull Med Suisse 2008; 89:165-169.
80. Hasse B, Ledergerber B, Hirschel B, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2010; 51:1314-1322.
81. Cohen MS. HIV treatment as prevention and 'The Swiss Statement': in for a dime, in for a dollar? Clin Infect Dis 2010; 51:1323-1324.
82. Novitsky V, Wang R, Bussmann H, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-and-treat' approach to reduce HIV transmission. PLoS One 2010; 5:e10148.
83. Dyer JR, Kazembe P, Vernazza PL, et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998; 177:1742-1746. (Pubitemid 28243608)
84. Ping LH, Nelson JAE, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 1999; 73:6271-6281. (Pubitemid 29327803)
85. Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:277-282.
86. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:249-258.
87. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
88. Powers K, Ghani A, Miller W, et al. The contribution of early HIV infection to HIV spread in Lilongwe, Malawi: implications for transmission prevention strategies. In: International AIDS Conference; 2010; Vienna, abstract FRLBC105, 2010.
89. Hightow LB, MacDonald PD, Pilcher CD, et al. The unexpected movement of the HIV epidemic in the southeastern United States: transmission among college students. J Acquir Immune Defic Syndr 2005; 38:531-537. (Pubitemid 40524474)
90. Pettifor A, Macphail C, Corneli A, et al. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav (in press).
91. Cohen MS, Shaw G, Haynes B, McMicael A. Acute HIV infection: basic, clinical and public health perspectives. New Engl J Med. Forthcoming 2011.